Carlsmed (CARL) Q1 2026 earnings review
Top-Line Momentum Continues, But Profitability Remains Elusive
Carlsmed delivered another quarter of rapid expansion, with Q1 revenue growing 58% YoY to $16.1 million. The successful rollout of new products like the corra cervical system and stellar clinical data publications prompted management to raise FY26 revenue guidance. However, top-line success is overshadowing a persistent lack of operating leverage. Operating expenses surged 62% YoY, outpacing revenue growth and widening the net loss to $8.7 million. While gross margins reached an impressive 77.1%, the company is burning cash to sustain its hyper-growth trajectory.
🐂 Bull Case
Gross margin hit a record 77.1% in Q1, accelerating from 74.9% a year ago. The company has moved past the manufacturing expedite fees that plagued 2025, proving its core unit economics are highly profitable.
A peer-reviewed study in the Global Spine Journal demonstrated a 74% reduction in reoperations for aprevo. This objective clinical data is a massive asset for hospital purchasing approvals.
🐻 Bear Case
Despite management previously pointing to future operating leverage, Q1 OpEx grew 62% YoY—outpacing the 58% revenue growth. Sales and Marketing alone jumped 53% to $10.3 million.
YoY revenue growth is decisively decelerating, stepping down from 98% in Q3, to 61% in Q4, and now 58% in Q1. Implied full-year guidance suggests a further slowdown to 48%.
⚖️ Verdict: ⚪
Neutral leaning Bullish. The company is executing its commercial strategy perfectly, launching new products on time and raising guidance. But investors should closely monitor the cash burn—rapid growth means little if the business model cannot scale without proportional cost increases.
Key Themes
Product Portfolio Expansion Executed on Schedule
Carlsmed successfully launched its corra personalized cervical plating system in February, marking its debut in the patient-specific fixation market. The company also completed the first aprevo bi-lateral posterior procedure. This execution unlocks entirely new revenue streams and supports the raised full-year guidance.
Gross Margins Accelerating to Record Levels
Gross margin expanded to 77.1%, up from 76.5% in Q4 and 74.9% a year ago. The reduction in production lead times to 6 days (achieved in late 2025) and the elimination of contract manufacturing expedite fees have established a highly profitable unit economic baseline.
Peer-Reviewed Data Bolsters Commercial Pitch
The publication in the Global Spine Journal showing a 74% reduction in revision rates for aprevo lumbar implants provides incontrovertible proof of value. When combined with the $21,125 NTAP reimbursement, Carlsmed now has a bulletproof pitch for hospital Value Analysis Committees (VACs).
Revenue Growth Trajectory is Decelerating
While 58% YoY revenue growth is impressive, the trajectory is decelerating. Growth fell from 99% in 25Q2, to 98% in 25Q3, to 61% in 25Q4. The raised FY26 guidance implies a 48% growth rate at the midpoint. This natural maturation of the business demands a shift in focus toward profitability.
Operating Leverage Remains Non-Existent
This data point directly contradicts the positive top-line narrative: despite $16.1 million in record revenue, Net Loss worsened to $8.7 million. Total operating expenses spiked 62% to $21.7M. If the company cannot scale sales without adding proportional S&M headcount ($10.3M this quarter), the path to breakeven will stretch significantly further into the future.
Potential Average Revenue Per Procedure (ARP) Dilution
During the previous quarter's call, management explicitly warned that the blended ARP would drop into the 'mid- to high $20,000' range in 2026 due to the lower-priced aprevo cervical product becoming a larger part of the mix. Investors must monitor whether higher cervical volumes can offset this pricing headwind.
Other KPIs
Stable compared to the -$8.2M run rate from late 2025, but representing a wider loss than the -$5.5M recorded in Q1 2025. Stock-based compensation surged to $1.6M (up 830% YoY), reflecting public company transition costs and headcount additions.
Down from $109.9 million at the end of 2025, reflecting a quarterly burn of approximately $12.8 million. Given the current trajectory, the balance sheet provides a comfortable multi-year runway, mitigating immediate dilution risks.
Guidance
Accelerating versus prior guidance of $70 - $75 million. The $74.5 million midpoint implies 48% YoY growth over FY25's $50.5 million. This reflects management's confidence in the early commercial momentum of the corra and aprevo cervical lines.
Key Questions
Operating Leverage Timeline
With Sales and Marketing expenses growing 53% YoY—nearly matching revenue growth—at what revenue threshold do you expect to see meaningful operating leverage?
New Product Revenue Contribution
Can you disaggregate the Q1 revenue beat? How much of the outperformance was driven by initial stocking or adoption of the new corra and aprevo cervical platforms versus base lumbar volume?
Pricing and ARP Mix
As expected, has the increased volume of cervical procedures begun to dilute the blended Average Revenue Per Procedure (ARP), and how did that metric trend sequentially in Q1?